Age-related macular degeneration is a leading cause of visual impairment and severe vision
loss. Clinically, it is classified as early-stage (medium-sized drusen and retinal pigmentary …

The introduction of anti-vascular endothelial growth factor (anti-VEGF) has made significant
impact on the reduction of the visual loss due to neovascular age-related macular …

Progression to exudative 'wet'age-related macular degeneration (exAMD) is a major cause
of visual deterioration. In patients diagnosed with exAMD in one eye, we introduce an …

Purpose: While millions of individuals show early age-related macular degeneration (AMD)
signs, yet have excellent vision, the risk of progression to advanced AMD with legal …

Clinical trials identified intravitreal vascular endothelial growth factor inhibitors (anti-VEGF
agents) have the potential to stabilise or even improve visual acuity outcomes in …

Purpose This study assessed anti–vascular endothelial growth factor (VEGF) therapy
intensity and its relationship with visual acuity (VA) change in real-world neovascular age …

Purpose: To report the efficacy and safety of intravitreal ranibizumab for neovascular age-
related macular degeneration (nAMD) in real-world practice. Methods: Metaanalysis of∼ …

Introduction: Investigational anti-VEGF treatments for neovascular age-related macular
degeneration (nAMD) aim to improve visual outcomes and reduce treatment burden; these …

Neovascular age-related macular degeneration (nAMD) treatment has been revolutionized
by the introduction of vascular endothelial growth factor antagonists (anti-VEGF), but the …

Purpose To assess the safety and efficacy of E10030 (Fovista; Ophthotech, New York, NY), a
platelet-derived growth factor (PDGF) antagonist, administered in combination with the anti …